Tenderwize
Wróć do wyszukiwania

Open house Arzneimittelrabattverträge Icatibant, ATC B06AC02

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline May 05, 2027 · 250 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Icatibant, ATC B06AC02

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

30 / 100

Czynniki ryzyka

No estimated value or maximum framework value provided; potential volume of rebates unknown.

Contract may be automatically terminated if another rebate contract for Icatibant is concluded; uncertainty.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Non-exclusive rebate agreements for the active ingredient Icatibant (ATC B06AC02) under §130a Abs. 8 SGB V.
  • Agreements are identical and non-negotiable; all qualified pharmaceutical companies can participate.
Pokaż pełne podsumowanie

AOK Bayern is conducting an open-house model for non-exclusive rebate agreements on the active ingredient Icatibant (ATC B06AC02) under §130a Abs. 8 SGB V. This is not a formal procurement procedure; any interested pharmaceutical company meeting eligibility criteria can conclude an identical, non-negotiable rebate agreement. The contract runs from 01.07.2025 to 30.06.2027, with possible termination on one month's notice. Agreements can be concluded at any time during the period, but no later than 05.05.2027. Submission requires a signed self-declaration of reliability and the signed contract, either in paper form (hand-signed, two copies) or electronically with a qualified electronic signature via the DTVP portal. Only pharmaceutical companies are eligible. Estimated value is not provided.

Ryzyka

No estimated value or maximum framework value provided; potential volume of rebates unknown.

Contract may be automatically terminated if another rebate contract for Icatibant is concluded; uncertainty.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Only pharmaceutical companies are eligible as potential contract partners.

Administrative

  • Submission of a signed self-declaration of reliability (Eigenerklärung zur Zuverlässigkeit).
  • Submission of the signed contract including the appendix 'Festlegung der vertragsgegenständlichen Arzneimittel'.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house Arzneimittelrabattverträge Icatibant, ATC B06AC02

Non-exclusive rebate agreements for the active ingredient Icatibant (ATC B06AC02) with AOK Bayern. Open to all interested pharmaceutical companies that meet the eligibility criteria. Identical, non-negotiable terms. Contract duration: 01.07.2025 to 30.06.2027.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Jun 2025 - Jun 2027

Kategoria

Pharmaceutical products

Termin

Deadline May 05, 2027

Szczegóły zamówienia

Data publikacji
15 May 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
317628-2025

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30